Elusys Therapeutics

Montville, United States Founded: 1999 • Age: 27 yrs
Antibody therapeutics for anthrax and infectious diseases are developed.

About Elusys Therapeutics

Elusys Therapeutics is a Healthcare company based in Montville (United States) founded in 1999. Antibody therapeutics for anthrax and infectious diseases are developed. Elusys Therapeutics has raised $50 million across 6 funding rounds from investors including NIH, Legg Mason and MedImmune Ventures. The company has 15 employees. Its chief executive, as recorded, is Elizabeth Posillico. Elusys Therapeutics offers products and services including ANTHIM. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is ELUSYS THERAPEUTICS, INC. Its competitors include BigHat, Kodiak Sciences and Visterra; 3 of its 3 listed competitors have raised funding.

Company details

Elusys Therapeutics was established in 1999 in Montville, United States, within the biotechnology sector. Focus is placed on developing antibody-based treatments for infectious diseases, with emphasis on anthrax. The FDA-approved product, Anthim (obiltoxaximab), a monoclonal antibody targeting anthrax toxins protective antigen, is used for treating inhalational anthrax in adults and children alongside antibacterial drugs, and for prophylaxis against the condition.

  • Headquarters Montville, United States
  • Employees 15
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website elusys.com
  • Social LinkedIn
  • Legal Name Elusys Therapeutics, Inc.
Key Metrics
  • Total Equity Funding
    $50M (USD)

    in 6 rounds

  • Latest Funding Round
    $23M (USD), Series D

    Jul 2006

  • Investors
    NIH

    & 8 more

  • Employee Count
    15

Products & Services of Elusys Therapeutics

Elusys Therapeutics offers a comprehensive portfolio of products and services, including ANTHIM.

ANTHIM
Biodefense Therapy

Monoclonal antibody for treating anthrax exposure effects

Funding Insights of Elusys Therapeutics

Elusys Therapeutics has successfully raised a total of $50M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $23 million completed in July 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $50M
  • Total Rounds 6
  • Last Round Series D — $23M
  • First Round $17M

    (Jul 2001)

  • Investors Count 9

All 6 funding rounds of Elusys Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2006$23MSeries D––
Aug 2005$5.4MGrant––
Aug 2004$10MSeries D––
Sep 2003$3.5MGrant––
Mar 2003$1.2MGrant––
Jul 2001$17MSeries C––
Valuation history

9 investors in total: 9 institutional.

Investors in Elusys Therapeutics

Elusys Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Legg Mason and MedImmune Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
medimmuneventures.com
crescendoventures.com
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
ewhealthcare.comNew York, United States
Diversified asset management services are offered globally by Invesco.
invesco.comAtlanta, United States
niaid.nih.gov
Military forces are provided by the U.S. Department of Defense for national security.
defense.govWashington, D.C., United States
Provides investment strategies for equities, energy infrastructure, and wealth management services.
1996eagleglobal.comHouston, United States
Drug discovery services are provided to the biopharma sector.
1887nih.govUnited States
Diversified investment management services are offered globally.
1899leggmason.comBaltimore, United States
Premium access

Investor details for Elusys Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Elusys Therapeutics

4 people are tracked at Elusys Therapeutics (3 in leadership, 1 in team); the tracked headcount is 15.

NameRoleGroup
Elizabeth Posillico
CEOLeadership
Vera Wong
Vice President - Finance / Corporate OfficerLeadership
Bob Love
Vice President & CFOLeadership
Nick Pagano
ControllerTeam
Premium access

Complete people profiles for Elusys Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Elusys Therapeutics

3 dated milestones of Elusys Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Elusys Therapeutics is founded.
  2. Funding First funding round of $17.0M.
  3. Funding Latest funding round, Series D, of $23.0M.

Competitors of Elusys Therapeutics

Elusys Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BigHat, Kodiak Sciences and Visterra.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
bighatbio.com2019San Carlos, United States$148.41M
Antibody therapies are developed through machine learning and synthetic biology.
kodiak.com2009Palo Alto, United States$35.84M112
Therapeutics for retinal diseases are developed by the company.
visterrainc.com2007Cambridge, United States$116.17M79
Developer of monoclonal antibodies against infectious diseases
Premium access

Detailed competitors of Elusys Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Elusys Therapeutics

The website of Elusys Therapeutics (elusys.com) receives about 1.4K visits a month.

  • Monthly visits
    1.4K

    ▼ 7.4% vs previous month

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Elusys Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Elusys Therapeutics

Frequently Asked Questions about Elusys Therapeutics

Elusys Therapeutics was founded in 1999 and raised its 1st funding round 2 years after it was founded.

Elusys Therapeutics is headquartered in Montville, United States. It is registered at Montville, New Jersey, United States.

Elizabeth Posillico is the CEO of Elusys Therapeutics, as recorded in our data.

Elusys Therapeutics is a funded company, having raised a total of $50M across 6 funding rounds to date. The company's 1st funding round was a Series C of $17M, raised on Jul 2001.

Elusys Therapeutics has 15 employees.

Elusys Therapeutics was established in 1999 in Montville, United States, within the biotechnology sector. Focus is placed on developing antibody-based treatments for infectious diseases, with emphasis on anthrax. The FDA-approved product, Anthim (obiltoxaximab), a monoclonal antibody targeting anthrax toxins protective antigen, is used for treating inhalational anthrax in adults and children alongside antibacterial drugs, and for prophylaxis against the condition.

Elusys Therapeutics's top competitors include Kodiak Sciences, Visterra and BigHat.

Elusys Therapeutics offers ANTHIM.

Elusys Therapeutics has 9 investors. Key investors include NIH, Legg Mason, MedImmune Ventures, Invesco, and Crescendo Ventures.

Elusys Therapeutics operates through Elusys Therapeutics, Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available